NASDAQ:ALKSAlkermes Stock Price, Forecast & News

$16.86

+0.28 (+1.69 %)

(As of 05/25/2020 04:00 PM ET)

Add

Compare

Today's Range

$16.42

Now: $16.86▼

$16.89

50-Day Range

$13.31

MA: $15.26▼

$16.85

52-Week Range

$11.98

Now: $16.86▼

$25.35

Volume775,978 shs

Average Volume1.64 million shs

Market Capitalization$2.68 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.4

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Beat the Market (BTM) Rank^™

4.0 Analyst's Opinion

Consensus Rating
Alkermes has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 1 buy rating, 11 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.17, Alkermes has a potential upside of 25.5% from its current price of $16.86.
Amount of Analyst Coverage
Alkermes has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.9 Community Rank

Outperform Votes
Alkermes has received 634 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Alkermes has received 468 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Alkermes has received 57.53% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote “Outperform” if you believe ALKS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Alkermes does not currently pay a dividend.
Dividend Growth
Alkermes does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,701,938.00 in company stock.
Percentage Held by Insiders
Only 4.49% of the stock of Alkermes is held by insiders.
Percentage Held by Institutions
97.90% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Alkermes are expected to grow in the coming year, from ($0.94) to ($0.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alkermes is -19.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alkermes is -19.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alkermes has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.71 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:ALKS

Previous Symbol

CUSIPG0176710

CIK1520262

Webwww.alkermes.com

Phone353-1772-8000

Debt

Debt-to-Equity Ratio0.26

Current Ratio2.69

Quick Ratio2.36

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.17 billion

Price / Sales2.29

Cash Flow$0.58 per share

Price / Cash Flow28.99

Book Value$6.89 per share

Price / Book2.45

Profitability

EPS (Most Recent Fiscal Year)$0.07

Net Income$-196,620,000.00

Net Margins-11.63%

Return on Equity4.99%

Return on Assets3.01%

Miscellaneous

Employees2,235

Outstanding Shares158,740,000

Market Cap$2.68 billion

Next Earnings Date7/23/2020 (Estimated)

OptionableOptionable

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

How has Alkermes' stock been impacted by COVID-19 (Coronavirus)?

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALKS stock has increased by 3.8% and is now trading at $16.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alkermes?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 11 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Alkermes.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Alkermes.

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) posted its quarterly earnings data on Wednesday, April, 29th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.07. The company earned $246.20 million during the quarter, compared to analysts' expectations of $230.53 million. Alkermes had a positive return on equity of 4.99% and a negative net margin of 11.63%. The firm's revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.17) EPS. View Alkermes' earnings history.

What price target have analysts set for ALKS?

12 analysts have issued 1 year price objectives for Alkermes' stock. Their forecasts range from $16.00 to $28.00. On average, they anticipate Alkermes' stock price to reach $21.17 in the next year. This suggests a possible upside of 25.5% from the stock's current price. View analysts' price targets for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:

1. According to Zacks Investment Research, "Alkermes reported impressive third-quarter results wherein both earnings and sales beat estimates. With increasing traction of Aristada in the market, Alkermes is emerging as a leader in the treatment of schizophrenia. This year will be an important one for the company’s late-stage pipeline owing to the planned submission of the NDA for ALKS 3831 for both schizophrenia and bipolar I disorder indications. The company also expects action on the regulatory review of the recently submitted NDA for Vumerity (diroximel fumarate) for multiple sclerosis in the fourth quarter. However, Alkermes is highly dependent on manufacturing and/or royalty revenues from partners, which is a concern. Shares have underperformed the industry year to date." (1/2/2020)
2. HC Wainwright analysts commented, "Valuation Our $28 price target for Alkermes is based on our sum-of-the-parts NPV valuation based on each of the company’s marketed products and pipeline assets. Our DCF model utilizes a discount rate of 13.1% based on the company’s WACC (Beta of 1.9, equity risk premium of 6.7%)." (5/31/2019)

Has Alkermes been receiving favorable news coverage?

Media stories about ALKS stock have trended very positive on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alkermes earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutAlkermes.

Are investors shorting Alkermes?

Alkermes saw a increase in short interest in April. As of April 30th, there was short interest totaling 9,290,000 shares, an increase of 16.6% from the April 15th total of 7,970,000 shares. Based on an average daily volume of 2,020,000 shares, the days-to-cover ratio is presently 4.6 days. Approximately 5.9% of the company's stock are sold short. View Alkermes' Current Options Chain.

Who are some of Alkermes' key competitors?

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Starbucks (SBUX), Alibaba Group (BABA), Walt Disney (DIS), Johnson & Johnson (JNJ) and Pfizer (PFE).

Who are Alkermes' key executives?

Alkermes' management team includes the following people:

Mr. Richard F. Pops, Chairman & CEO (Age 57)
Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
Mr. James M. Frates, Sr. VP & CFO (Age 52)
Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)
Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51)

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Management Group LLP (13.82%), Primecap Management Co. CA (5.67%), BlackRock Inc. (5.55%), Sarissa Capital Management LP (4.53%), Camber Capital Management LP (3.81%) and State Street Corp (2.98%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, Iain Michael Brown, James M Frates, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops. View institutional ownership trends for Alkermes.

Which major investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Two Sigma Investments LP, BlackRock Inc., Deutsche Bank AG, Engineers Gate Manager LP, Rafferty Asset Management LLC, Spark Investment Management LLC, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, Michael J Landine, and Richard F Pops. View insider buying and selling activity for Alkermes.

Which major investors are buying Alkermes stock?

ALKS stock was purchased by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Maverick Capital Ltd., Camber Capital Management LP, BNP Paribas Arbitrage SA, Invesco Ltd., Atom Investors LP, UBS Group AG, and Krensavage Asset Management LLC. View insider buying and selling activity for Alkermes.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $16.86.

How big of a company is Alkermes?

Alkermes has a market capitalization of $2.68 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

What is Alkermes' official website?

The official website for Alkermes is www.alkermes.com.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff